HRTX vs. HROW, ADCT, NATR, ATAI, NKTX, PGEN, TERN, ESPR, URGN, and RVNC
Should you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Harrow Health (HROW), ADC Therapeutics (ADCT), Nature's Sunshine Products (NATR), Atai Life Sciences (ATAI), Nkarta (NKTX), Precigen (PGEN), Terns Pharmaceuticals (TERN), Esperion Therapeutics (ESPR), UroGen Pharma (URGN), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Harrow Health (NASDAQ:HROW) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.
Heron Therapeutics received 576 more outperform votes than Harrow Health when rated by MarketBeat users. Likewise, 68.95% of users gave Heron Therapeutics an outperform vote while only 55.63% of users gave Harrow Health an outperform vote.
Harrow Health has a net margin of -18.75% compared to Harrow Health's net margin of -87.02%. Harrow Health's return on equity of 0.00% beat Heron Therapeutics' return on equity.
72.8% of Harrow Health shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 13.6% of Harrow Health shares are owned by company insiders. Comparatively, 6.4% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Harrow Health presently has a consensus price target of $28.13, suggesting a potential upside of 171.03%. Heron Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 110.73%. Given Heron Therapeutics' higher probable upside, equities analysts plainly believe Harrow Health is more favorable than Heron Therapeutics.
In the previous week, Harrow Health had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Harrow Health and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.54 beat Harrow Health's score of 0.11 indicating that Harrow Health is being referred to more favorably in the media.
Harrow Health has higher revenue and earnings than Heron Therapeutics. Harrow Health is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Harrow Health has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.
Summary
Harrow Health beats Heron Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Heron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Heron Therapeutics Competitors List
Related Companies and Tools
